Skip to main content
Contact Us
Subscribe
E-Edition
86°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by NICOX
Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting
April 09, 2024
From
NICOX
Via
GlobeNewswire
Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology
March 20, 2024
From
NICOX
Via
GlobeNewswire
Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024
March 13, 2024
From
NICOX
Via
GlobeNewswire
Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting
March 05, 2024
From
NICOX
Via
GlobeNewswire
Nicox Appoints Experienced Biotech Executive Gavin Spencer as CEO
February 28, 2024
From
NICOX
Via
GlobeNewswire
Nicox Restructures Debt, Streamlines Operations to Extend Cash Runway and Focus Resources on NCX 470 Pivotal Trial
February 28, 2024
From
NICOX
Via
GlobeNewswire
Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japan
February 08, 2024
From
NICOX
Via
GlobeNewswire
Nicox announces presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024
February 06, 2024
From
NICOX
Via
GlobeNewswire
Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA®
January 31, 2024
From
NICOX
Via
GlobeNewswire
Nicox Provides Fourth Quarter 2023 Financial and Business Highlights
January 25, 2024
From
NICOX
Via
GlobeNewswire
Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucoma
December 18, 2023
From
NICOX
Via
GlobeNewswire
Nicox’s Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 compared to Lumigan
December 14, 2023
From
NICOX
Via
GlobeNewswire
Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Updates Key Milestones
October 20, 2023
From
NICOX
Via
GlobeNewswire
Nicox Provides Second Quarter 2023 Financial and Business Highlights
July 19, 2023
From
NICOX
Via
GlobeNewswire
Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million
July 10, 2023
From
NICOX
Via
GlobeNewswire
Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis Showing Superiority over Latanoprost at the World Glaucoma Congress
July 03, 2023
From
NICOX
Via
GlobeNewswire
Nicox’s Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China
April 28, 2023
From
NICOX
Via
GlobeNewswire
Transfer of Nicox’s shares to Euronext Growth Paris effective on April 28, 2023
April 26, 2023
From
NICOX
Via
GlobeNewswire
New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023
April 26, 2023
From
NICOX
Via
GlobeNewswire
Nicox Provides First Quarter 2023 Financial and Business Highlights
April 19, 2023
From
NICOX
Via
GlobeNewswire
Additional Future Royalty Revenue Stream for Nicox from 2024 following New Drug Application Submission for ZERVIATE in China
April 14, 2023
From
NICOX
Via
GlobeNewswire
Nicox Announces Presentations of Additional NCX 470 Data at the Upcoming World Glaucoma Congress
March 21, 2023
From
NICOX
Via
GlobeNewswire
Nicox Reports 2022 Financial Results and Updates Key Future Milestones
March 20, 2023
From
NICOX
Via
GlobeNewswire
Nicox to Present at Upcoming Scientific Conferences
March 03, 2023
From
NICOX
Via
GlobeNewswire
Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 2023
January 24, 2023
From
NICOX
Via
GlobeNewswire
Nicox Provides Fourth Quarter 2022 Financial Highlights
January 18, 2023
From
NICOX
Via
GlobeNewswire
Nicox Announces Proposed Move to Euronext Growth Paris
January 09, 2023
From
NICOX
Via
GlobeNewswire
Nicox Outlines Future Development and Partnering Plans for NCX 470 in Glaucoma
November 07, 2022
From
NICOX
Via
GlobeNewswire
Nicox Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470
October 31, 2022
From
NICOX
Via
GlobeNewswire
Nicox Provides Third Quarter 2022 Financial and Business Highlights
October 19, 2022
From
NICOX
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.